Taxol is active in platinum-resistant endometrial adenocarcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 3, 1996, Pages 290-291

  Woo, H L ^a   Swenerton, K D ^a   Hoskins, P J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Endometrial adenocarcinoma; Platinum resistance; Taxol

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN;

ADENOCARCINOMA; ADULT; AGED; CISPLATIN; DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL;

EID: 0029999183     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199606000-00016     Document Type: Article

References (15)

1. Petterson F. Annual report on the results of treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics, 1991:132-53.
2. Trope C, Johnsson JE, Simonsen E, et al. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 1984;149:379-81.
3. Lovecchio JL, Averette HE, Lichtinger M, et al. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cisplatinum and megestrol acetate. Obstet Gynecol 1984;63:557-60.
4. Pasmantier MW, Coleman M, Silver RT, et al. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer Treat Rep 1985;69:539-42.
5. Burke TW, Stringer CA, Morris M, et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 1991;40: 264-7.
6. Burke TW, Munkarah A, Kavanagh JJ, et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 1993;51:397-400.
7. Valero V, Esparza L, Holmes F, et al. Phase II study of taxotere in refractory metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1993;12:96.
8. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
9. Seidman AD, Norton L, Reichman BS, et al. Preliminary experience with paclitaxel (TAXOL) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 1993;20:40-5.
10. Brockstein B, Fleming G, Williams S. Paclitaxel for metastatic breast cancer after progression from high dose chemotherapy with autologous stem cell transplant: safety, efficacy, and lack of marrow suppression [Abstract]. Proc Am Soc Clin Oncol 1994;13:101.
11. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
12. Einzig AI, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-53.
13. Thigpen T, Blessing J, Ball H, et al. Phase II trial of taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study [Abstract]. Proc Am Soc Clin Oncol 1990;9: 156.
14. Swenerton KD, Eisenhauer E, ten Bokkel Huinink W, et al. Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion, European-Canadian randomized trial of taxol in relapsed ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1993;12:256.
15. Gelman KA, O'Reilly S, Plenderleith IH, et al. Biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 1994;13:71.